EB病毒感染相关性噬血细胞性淋巴组织细胞增多症的研究进展
|
摘要
<正>噬血细胞性淋巴组织细胞增多症(hemophagocytic lymphohistiocytosis,HLH)又称噬血细胞综合征,是一种罕见的致命性免疫调节异常综合征,以过度的免疫反应及过度活化的巨噬细胞和T淋巴细胞广泛浸润各组织器官,导致多器官系统功能衰竭为特征~([1])。HLH包括原发性和继发性两种类型。其中继发性HLH主要由感染、肿瘤、风湿免
Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis(EBV-HLH)is one of the most common forms of the secondary HLH.Patients diagnosed as having EBV-HLH was based on fulfilling the HLH-2004 criteria and the diagnosis of EBV infection.HLH-2004 protocol is still the first choice of the treatment of EBV-HLH.In recent years,as the research continues on how to treat EBV-HLH,more and more individual and stratified therapeutic strategies have been chosen.In this review,the research progress on the epidemiology,pathogenesis,diagnosis,therapy and prognosis of EBV-HLH have been summarized.
Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis(EBV-HLH)is one of the most common forms of the secondary HLH.Patients diagnosed as having EBV-HLH was based on fulfilling the HLH-2004 criteria and the diagnosis of EBV infection.HLH-2004 protocol is still the first choice of the treatment of EBV-HLH.In recent years,as the research continues on how to treat EBV-HLH,more and more individual and stratified therapeutic strategies have been chosen.In this review,the research progress on the epidemiology,pathogenesis,diagnosis,therapy and prognosis of EBV-HLH have been summarized.
引文
[1]Hashemi-Sadraei N,Vejpongsa P,Baljevic M,et al.Epstein-Barr virus-related hemophagocytic lymphohistiocytosis:hematologic emergency in the critical care setting[J].Case Rep Hematol,2015,2015:491567.
[2]裴瑞君,王昭,王旖旎,等.全国多中心噬血细胞性淋巴组织细胞增多症601例病因分析[J].中华内科杂志,2015,54(12):1018-1022.
[3]Wang Y,Ai J,Xie Z,et al.IL-10-592 A/C polymorphisms is associated with EBV-HLH in Chinese children[J].Hematology,2016,21:95-98.
[4]Ishii E,Ohga S,Imashuku S,et al.Nationwide survey of hemophagocytic lymphohistiocytosis in Japan[J].Int J Hematol,2007,86:58-65.
[5]Nanbo A,Kachi K,Yoshiyama H,et al.Epstein-Barr virus exploits host endocytic machinery for cell-to-cell viral transmission rather than a virological synapse[J].J Gen Virol,2016,97:2989-3006.
[6]Nawathe PA,Ravindranath TM,Satwani P,et al.Severe hemorrhagic coagulopathy with hemophagocytic lymphohistiocytosis secondary to Epstein-Barr virusassociated T-cell lymphoproliferative disorder[J].Pediatr Crit Care Med,2013,14:e176-e181.
[7]吴小容,王建林,段子渊.慢性活动型EB病毒感染的致病机理研究进展[J].生物化学与生物物理进展,2016,43(10):980-989.
[8]Thorley-Lawson DA.EBV Persistence——Introducing the Virus[J].Curr Top Microbiol Immunol,2015,390:151-209.
[9]秦强,谢正德,刘春艳,等.儿童EB病毒相关噬血细胞性淋巴组织细胞增生症NK细胞表面受体和CD107a表达[J].中国循证儿科杂志,2012,7(2):136-140.
[10]Henter JI,Horne A,AricóM,et al.HLH-2004:Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis[J].Pediatr Blood Cancer,2007,48:124-131.
[11]马晨,张泓.儿童EB病毒感染的实验室诊断[J].中华检验医学杂志,2015,38(4):3468-3469.
[12]史利欢,刘炜,栗春香.儿童EB病毒相关性嗜血淋巴组织细胞增生症的病毒学特征[J].临床医药文献杂志,2015,2(31):6526-6527.
[13]刘嵘,师晓东,李君惠,等.儿童EB病毒相关性噬血性淋巴组织细胞增生症的临床特征及相关基因缺陷[J].中华医学杂志,2014,94(25):1941-1946.
[14]MR George.Hemophagocytic lymphohistiocytosis:review of etiologies and management[J].J Blood Med,2014,5:69-86.
[15]李国辉,范玉贞,郝淼旺,等.噬血细胞综合征30例临床分析[J].临床血液学杂志,2011,24(5):276-278.
[16]Imashuku S,Kuriyama K,Sakai R,et al.Treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis(EBV-HLH)in young adults:a report from the HLH study center[J].Med Pediatr Oncol,2003,41:103-109.
[17]李文益,薛红漫.EB病毒感染相关性噬血细胞综合征的发病机制、诊断和治疗[J].中华妇幼临床医学杂志(电子版),2011,7(2):77-81.
[18]George MR.Hemophagocytic lymphohistiocytosis:review of etiologies and management[J].J Blood Med,2014,5:69-86.
[19]Seo JJ.Hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis:recent advances and controversies[J].Blood Res,2015,50:131-139.
[20]Qin Q,Xie Z,Shen Y,et al.Assessment of immunochemotherapy and stem cell transplantation on EBV-associated hemophagocytic lymphohistiocytosis in children:a systematic review and meta analysis[J].Eur Rev Med Pharmacol Sci,2012,16:672-678.
[21]Chellapandian DB,Das R,Zelley K,et al.Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens[J].Br J Haematol,2013,162:376-382.
[22]Imashuku S.Treatment of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis(EBV-HLH);update 2010[J].J Pediatr Hematol Oncol,2011,33:35-39.
[23]La Rosée P.Treatment of hemophagocytic lymphohistiocytosis in adults[J].Hematology Am Soc Hematol Educ Program,2015,2015:190-196.
[24]Kogawa K,Sato H,Asano T,et al.Prognostic factors of Epstein-Barr virus-associated hemophagocytic lymphohistio-cytosis in children:report of the Japan Histiocytosis Study Group[J].Pediatric Blood Cancer,2014,61:1257-1262.
[25]杜兴冉,徐喨,蔡洁,等.EB病毒相关噬血细胞性淋巴组织细胞增生症的临床特征及预后危险因素分析[J].中华临床感染病杂志,2014,7(2):111-115.
[2]裴瑞君,王昭,王旖旎,等.全国多中心噬血细胞性淋巴组织细胞增多症601例病因分析[J].中华内科杂志,2015,54(12):1018-1022.
[3]Wang Y,Ai J,Xie Z,et al.IL-10-592 A/C polymorphisms is associated with EBV-HLH in Chinese children[J].Hematology,2016,21:95-98.
[4]Ishii E,Ohga S,Imashuku S,et al.Nationwide survey of hemophagocytic lymphohistiocytosis in Japan[J].Int J Hematol,2007,86:58-65.
[5]Nanbo A,Kachi K,Yoshiyama H,et al.Epstein-Barr virus exploits host endocytic machinery for cell-to-cell viral transmission rather than a virological synapse[J].J Gen Virol,2016,97:2989-3006.
[6]Nawathe PA,Ravindranath TM,Satwani P,et al.Severe hemorrhagic coagulopathy with hemophagocytic lymphohistiocytosis secondary to Epstein-Barr virusassociated T-cell lymphoproliferative disorder[J].Pediatr Crit Care Med,2013,14:e176-e181.
[7]吴小容,王建林,段子渊.慢性活动型EB病毒感染的致病机理研究进展[J].生物化学与生物物理进展,2016,43(10):980-989.
[8]Thorley-Lawson DA.EBV Persistence——Introducing the Virus[J].Curr Top Microbiol Immunol,2015,390:151-209.
[9]秦强,谢正德,刘春艳,等.儿童EB病毒相关噬血细胞性淋巴组织细胞增生症NK细胞表面受体和CD107a表达[J].中国循证儿科杂志,2012,7(2):136-140.
[10]Henter JI,Horne A,AricóM,et al.HLH-2004:Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis[J].Pediatr Blood Cancer,2007,48:124-131.
[11]马晨,张泓.儿童EB病毒感染的实验室诊断[J].中华检验医学杂志,2015,38(4):3468-3469.
[12]史利欢,刘炜,栗春香.儿童EB病毒相关性嗜血淋巴组织细胞增生症的病毒学特征[J].临床医药文献杂志,2015,2(31):6526-6527.
[13]刘嵘,师晓东,李君惠,等.儿童EB病毒相关性噬血性淋巴组织细胞增生症的临床特征及相关基因缺陷[J].中华医学杂志,2014,94(25):1941-1946.
[14]MR George.Hemophagocytic lymphohistiocytosis:review of etiologies and management[J].J Blood Med,2014,5:69-86.
[15]李国辉,范玉贞,郝淼旺,等.噬血细胞综合征30例临床分析[J].临床血液学杂志,2011,24(5):276-278.
[16]Imashuku S,Kuriyama K,Sakai R,et al.Treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis(EBV-HLH)in young adults:a report from the HLH study center[J].Med Pediatr Oncol,2003,41:103-109.
[17]李文益,薛红漫.EB病毒感染相关性噬血细胞综合征的发病机制、诊断和治疗[J].中华妇幼临床医学杂志(电子版),2011,7(2):77-81.
[18]George MR.Hemophagocytic lymphohistiocytosis:review of etiologies and management[J].J Blood Med,2014,5:69-86.
[19]Seo JJ.Hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis:recent advances and controversies[J].Blood Res,2015,50:131-139.
[20]Qin Q,Xie Z,Shen Y,et al.Assessment of immunochemotherapy and stem cell transplantation on EBV-associated hemophagocytic lymphohistiocytosis in children:a systematic review and meta analysis[J].Eur Rev Med Pharmacol Sci,2012,16:672-678.
[21]Chellapandian DB,Das R,Zelley K,et al.Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens[J].Br J Haematol,2013,162:376-382.
[22]Imashuku S.Treatment of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis(EBV-HLH);update 2010[J].J Pediatr Hematol Oncol,2011,33:35-39.
[23]La Rosée P.Treatment of hemophagocytic lymphohistiocytosis in adults[J].Hematology Am Soc Hematol Educ Program,2015,2015:190-196.
[24]Kogawa K,Sato H,Asano T,et al.Prognostic factors of Epstein-Barr virus-associated hemophagocytic lymphohistio-cytosis in children:report of the Japan Histiocytosis Study Group[J].Pediatric Blood Cancer,2014,61:1257-1262.
[25]杜兴冉,徐喨,蔡洁,等.EB病毒相关噬血细胞性淋巴组织细胞增生症的临床特征及预后危险因素分析[J].中华临床感染病杂志,2014,7(2):111-115.